There are now three FDA-approved CDK4/6i (palbociclib, abemaciclib, and ribociclib) that prevent the expression of E2F target genes and halt cancer cells in the G1 phase of the cell cycle (26, 27, 28). The gene discussed is CDK4; the disease is cancer.